Alpha Cubed Investments LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Alpha Cubed Investments LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 269 shares of the biopharmaceutical company’s stock after selling 27 shares during the quarter. Alpha Cubed Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $283,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Greenfield Savings Bank boosted its stake in shares of Regeneron Pharmaceuticals by 28.6% during the third quarter. Greenfield Savings Bank now owns 612 shares of the biopharmaceutical company’s stock valued at $643,000 after purchasing an additional 136 shares during the period. Miracle Mile Advisors LLC boosted its position in Regeneron Pharmaceuticals by 12.6% during the 3rd quarter. Miracle Mile Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $2,693,000 after buying an additional 286 shares during the period. GAMMA Investing LLC boosted its position in Regeneron Pharmaceuticals by 32.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock valued at $1,510,000 after buying an additional 353 shares during the period. MRA Advisory Group bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $455,000. Finally, Park Avenue Securities LLC increased its position in shares of Regeneron Pharmaceuticals by 7.6% in the third quarter. Park Avenue Securities LLC now owns 1,889 shares of the biopharmaceutical company’s stock valued at $1,986,000 after acquiring an additional 134 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on REGN shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. Wells Fargo & Company reiterated an “overweight” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, September 23rd. Truist Financial reissued a “buy” rating and set a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Piper Sandler raised their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Finally, Royal Bank of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,119.00.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,033 shares of company stock valued at $9,399,345. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ:REGN opened at $1,005.26 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The stock has a market capitalization of $110.77 billion, a price-to-earnings ratio of 29.51, a PEG ratio of 3.55 and a beta of 0.12. The stock has a fifty day simple moving average of $1,124.02 and a two-hundred day simple moving average of $1,038.18. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the business posted $8.79 EPS. Regeneron Pharmaceuticals’s revenue was up 12.3% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.